This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The list also includes non-hallucinogenic drugs related to hallucinogens, such as non-hallucinogenic serotonin 5-HT2A receptor agonists and non-hallucinogenic ketamine analogues. Cannabinoids, or cannabinoid receptor modulators, are not included in this list. Many of the indications are not for continuous medication therapy but rather are for medication-assisted psychotherapy or short-term use only. The section that the drug is in corresponds to its highest developmental phase, not its phase for all listed indications. This list was last comprehensively updated in October 2024. It is likely to become outdated with time.
Under development
Preregistration Midomafetamine (MDMA; "ecstasy") – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen – post-traumatic stress disorder, alcoholism, social anxiety in autism – Multidisciplinary Association for Psychedelic Studies (MAPS), Resilient Pharmaceuticals (Lykos Therapeutics)
Phase 3 Deupsilocin (HLP003; HLP-003; CYB003; CYB-003; psilocin-d10; deuterated psilocybin analogue; deuterated psilocin) – serotonin 5-HT2A receptor agonist and psychedelic hallucinogen – major depressive disorder, alcoholism, psychiatric disorders – Helus Pharma (Cybin) Ketamine (AWKN-001, AWKN-P-001) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – alcoholism, binge-eating disorder, gambling, impulse control disorders, obsessive–compulsive disorder – Awakn Life Sciences Ketamine (HTX-100; NRX-100) – ionotropic glutamate NMDA receptor antagonist – suicidal ideation, mental disorders – NRx Pharmaceuticals Lysergic acid diethylamide (LSD; lysergide; DT120; DT-120; MM120; MM-120) – non-selective serotonin receptor agonist and psychedelic hallucinogen – anxiety disorders, attention-deficit hyperactivity disorder, cluster headache, major depressive disorder, pain – Definium Therapeutics (MindMed) Lysergic acid diethylamide (LSD; lysergide; MB-22001/MB22001) – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder, existential distress in cancer patients – MindBio Therapeutics Psilocybin (COMP-360; COMP360) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders, anorexia nervosa, bipolar depression, major depressive disorder, post-traumatic stress disorder, somatoform disorders, pervasive child development disorders – COMPASS Pathways Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder, borderline personality disorder – Usona Institute
… excerpt ends here. Continue reading the full article.

